Polaryx Therapeutics, Inc.
corporate_fare Company Profile
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for PLYX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PLYX spans 10-Q, 4, 8-K, 10-K.
Recent high-impact activity:
- Polaryx Q3 10-Q: Going Concern Reaffirmed, $8.4M Cash Funds Operations Only Through Q1 2027
- Polaryx Q2 2026: Going Concern Warning, Cash Runway to Q1 2027, SOTERIA Trial Expanded
- CEO Alex Yang Buys $360K in Polaryx Therapeutics Stock at Significant Premium
- Polaryx Therapeutics Secures $10M Private Placement at Premium to Fund Phase 2 Trial, Extends Runway
- $10M Equity Financing Closes for Polaryx, Funds Phase 2 Trial
Financial Snapshot
Short Interest & Short Volume
6.48 days to coverFINRA reported short interest of 138,265 shares in PLYX as of the October 30, 2026 settlement, a 16.9% increase from the prior period — about 6.5 days to cover at its recent average daily volume. On November 20, 2026, 51.2% of PLYX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.